ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.58 Billion KRW | 0.0% |
| 2022 | 9.82 Billion KRW | 9.0% |
| 2021 | 9.01 Billion KRW | -53.12% |
| 2020 | 19.22 Billion KRW | 167.06% |
| 2019 | 7.19 Billion KRW | 139.13% |
| 2018 | 3.01 Billion KRW | -79.83% |
| 2017 | 14.92 Billion KRW | 78.29% |
| 2016 | 8.37 Billion KRW | -47.96% |
| 2015 | 16.08 Billion KRW | -2.79% |
| 2014 | 16.54 Billion KRW | 24.98% |
| 2013 | 13.24 Billion KRW | -25.41% |
| 2012 | 17.75 Billion KRW | 21.4% |
| 2011 | 14.62 Billion KRW | 44.79% |
| 2010 | 10.09 Billion KRW | -14.05% |
| 2009 | 11.74 Billion KRW | -5.26% |
| 2008 | 12.4 Billion KRW | -12.96% |
| 2007 | 14.24 Billion KRW | 82.03% |
| 2006 | 7.82 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.05 Billion KRW | 23.13% |
| 2023 Q4 | 1.94 Billion KRW | -21.77% |
| 2023 Q3 | 2.49 Billion KRW | -10.61% |
| 2023 FY | 9.82 Billion KRW | 0.0% |
| 2023 Q1 | 2.74 Billion KRW | 41.13% |
| 2023 Q2 | 2.78 Billion KRW | 1.32% |
| 2022 Q2 | 2.1 Billion KRW | -37.25% |
| 2022 FY | 9.82 Billion KRW | 9.0% |
| 2022 Q4 | 1.94 Billion KRW | -19.25% |
| 2022 Q3 | 2.41 Billion KRW | 14.53% |
| 2022 Q1 | 3.35 Billion KRW | 0.0% |
| 2021 Q3 | 6.32 Billion KRW | 32.44% |
| 2021 FY | 9.01 Billion KRW | -53.12% |
| 2021 Q1 | 5.21 Billion KRW | -13.75% |
| 2021 Q2 | 4.77 Billion KRW | -8.4% |
| 2020 Q4 | 6.04 Billion KRW | 20.45% |
| 2020 FY | 19.22 Billion KRW | 167.06% |
| 2020 Q1 | 4.34 Billion KRW | 14.19% |
| 2020 Q2 | 3.82 Billion KRW | -11.87% |
| 2020 Q3 | 5.01 Billion KRW | 31.02% |
| 2019 Q1 | 1.3 Billion KRW | 114.12% |
| 2019 FY | 7.19 Billion KRW | 139.13% |
| 2019 Q3 | 3.77 Billion KRW | 324.51% |
| 2019 Q2 | -1.68 Billion KRW | -229.09% |
| 2019 Q4 | 3.8 Billion KRW | 0.78% |
| 2018 FY | 3.01 Billion KRW | -79.83% |
| 2018 Q3 | 3.83 Billion KRW | -2.95% |
| 2018 Q4 | -9.22 Billion KRW | -340.64% |
| 2018 Q1 | 4.45 Billion KRW | 28.3% |
| 2018 Q2 | 3.94 Billion KRW | -11.31% |
| 2017 FY | 14.92 Billion KRW | 78.29% |
| 2017 Q2 | 3.4 Billion KRW | 18.05% |
| 2017 Q3 | 5.16 Billion KRW | 51.65% |
| 2017 Q1 | 2.88 Billion KRW | -8.88% |
| 2017 Q4 | 3.46 Billion KRW | -32.82% |
| 2016 FY | 8.37 Billion KRW | -47.96% |
| 2016 Q2 | 2.62 Billion KRW | 14.02% |
| 2016 Q3 | 272.29 Million KRW | -89.64% |
| 2016 Q4 | 3.16 Billion KRW | 1062.7% |
| 2016 Q1 | 2.3 Billion KRW | -34.38% |
| 2015 Q1 | 3.85 Billion KRW | -0.0% |
| 2015 Q4 | 3.51 Billion KRW | -23.1% |
| 2015 Q3 | 4.56 Billion KRW | 9.95% |
| 2015 FY | 16.08 Billion KRW | -2.79% |
| 2015 Q2 | 4.15 Billion KRW | 7.83% |
| 2014 Q3 | 3.8 Billion KRW | -24.1% |
| 2014 Q1 | 3.85 Billion KRW | 53.65% |
| 2014 FY | 16.54 Billion KRW | 24.98% |
| 2014 Q2 | 5.01 Billion KRW | 30.05% |
| 2014 Q4 | 3.85 Billion KRW | 1.15% |
| 2013 Q2 | 3.15 Billion KRW | -6.41% |
| 2013 FY | 13.24 Billion KRW | -25.41% |
| 2013 Q4 | 2.51 Billion KRW | -40.22% |
| 2013 Q3 | 4.2 Billion KRW | 33.09% |
| 2013 Q1 | 3.37 Billion KRW | -34.29% |
| 2012 FY | 17.75 Billion KRW | 21.4% |
| 2012 Q2 | 3.98 Billion KRW | -13.1% |
| 2012 Q3 | 4.04 Billion KRW | 1.33% |
| 2012 Q4 | 5.13 Billion KRW | 27.0% |
| 2012 Q1 | 4.58 Billion KRW | 0.0% |
| 2011 Q3 | 1.27 Billion KRW | -19.66% |
| 2011 Q2 | 1.58 Billion KRW | 38.11% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 1.14 Billion KRW | 0.0% |
| 2011 FY | 14.62 Billion KRW | 44.79% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 1.54 Billion KRW | 0.0% |
| 2010 Q2 | 1.08 Billion KRW | -29.45% |
| 2010 Q3 | 1.03 Billion KRW | -5.33% |
| 2010 FY | 10.09 Billion KRW | -14.05% |
| 2009 Q1 | 1.28 Billion KRW | 0.0% |
| 2009 Q2 | 1.38 Billion KRW | 7.81% |
| 2009 Q3 | 1.18 Billion KRW | -14.8% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 11.74 Billion KRW | -5.26% |
| 2008 Q1 | 1.38 Billion KRW | 0.0% |
| 2008 Q3 | 1.07 Billion KRW | -45.85% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 12.4 Billion KRW | -12.96% |
| 2008 Q2 | 1.98 Billion KRW | 43.27% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 14.24 Billion KRW | 82.03% |
| 2007 Q1 | 975.32 Million KRW | 0.0% |
| 2007 Q3 | 1.19 Billion KRW | 12.28% |
| 2007 Q2 | 1.06 Billion KRW | 9.21% |
| 2006 FY | 7.82 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Green Cross Holdings Corporation | 603.58 Billion KRW | 98.412% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | 97.91% |
| Pharmicell Co., Ltd. | 14.95 Billion KRW | 35.913% |
| Green Cross Corporation | 458.68 Billion KRW | 97.91% |
| GeneOne Life Science, Inc. | -14.98 Billion KRW | 163.963% |
| Celltrion, Inc. | 1010.9 Billion KRW | 99.052% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 99.468% |
| SK bioscience Co.,Ltd. | 142.24 Billion KRW | 93.262% |
| SK Biopharmaceuticals Co., Ltd. | 308.37 Billion KRW | 96.892% |
| Prestige BioPharma Limited | 689.07 Million KRW | -1290.909% |